Evidence map›Paper›PMID 34184083›Full record

ArticleMolecular medicine reports2021

M2‑like tumour‑associated macrophage‑secreted IGF promotes thyroid cancer stemness and metastasis by activating the PI3K/AKT/mTOR pathway.

Juan Lv, Chao Liu, Fu-Kun Chen, Zhi-Ping Feng, Li Jia, Peng-Jie Liu, Zhi-Xian Yang, Fei Hou, Zhi-Yong Deng

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
5.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 76 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. The role of IGF/IGF-1R signaling in the regulation of cancer stem cells.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Juan LvDepartment of Nuclear Medicine, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650118, P.R. China.
Chao LiuDepartment of Nuclear Medicine, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650118, P.R. China.
Fu-Kun ChenDepartment of Nuclear Medicine, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650118, P.R. China.
Zhi-Ping FengDepartment of Nuclear Medicine, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650118, P.R. China.
Li JiaDepartment of Nuclear Medicine, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650118, P.R. China.
Peng-Jie LiuDepartment of Nuclear Medicine, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650118, P.R. China.
Zhi-Xian YangDepartment of Nuclear Medicine, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650118, P.R. China.
Fei HouDepartment of Nuclear Medicine, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650118, P.R. China.
Zhi-Yong DengDepartment of Nuclear Medicine, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650118, P.R. China.
Kunming Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

M2‑like tumour‑associated macrophages (TAMs) have been demonstrated to promote the growth of anaplastic thyroid carcinoma (ATC). However, the underlying mechanism of M2‑like TAMs in ATC remains unclear. Thus, in the present study, the role and mechanism of M2‑like TAMs in ATC were investigated. M2‑like TAMs were induced by treatment with PMA, plus IL‑4 and IL‑13, and identified by flow cytometry. Transwell and sphere formation assays were applied to assess the invasion and stemness of ATC cells. The expression levels of insulin‑like growth factor (IGF)‑1 and IGF‑2 were examined by ELISA and reverse transcription‑quantitative PCR. Proteins related to the epithelial‑mesenchymal transition (EMT), stemness and the PI3K/AKT/mTOR pathway were examined via western blotting. Immunohistochemistry (IHC) was used to detect the expression of the M2‑like TAM markers CD68 and CD206 in ATC tissues and thyroid adenoma tissues. It was found that treatment with PMA plus IL‑4 and IL‑13 successfully induced M2‑like TAMs. Following co‑culture with M2‑like TAMs, the invasive ability and stemness of ATC cells were significantly increased. The expression levels of the EMT‑related markers N‑cadherin and Vimentin, the stemness‑related markers Oct4, Sox2 and CD133, and the insulin receptor (IR)‑A/IGF1 receptor (IGF1R) were markedly upregulated, whereas E‑cadherin expression was significantly decreased. In addition, the production of IGF‑1 and IGF‑2 was significantly increased. Of note, exogenous IGF‑1/IGF‑2 promoted the invasion and stemness of C643 cells, whereas blocking IGF‑1 and IGF‑2 inhibited metastasis and stemness by repressing IR‑A/IGF‑1R‑mediated PI3K/AKT/mTOR signalling in the co‑culture system. IHC results showed that the expression of CD68 and CD206 was obviously increased in ATC tissues. To conclude, M2‑like TAMs accelerated the metastasis and increased the stemness of ATC cells, and the underlying mechanism may be related to the section of IGF by M2‑like TAMs, which activates the IR‑A/IGF1R‑mediated PI3K/AKT/mTOR signalling pathway.

Indexed as

Neoplastic Stem CellsSignal TransductionAdultAgedAntibodies, NeutralizingAntigens, CDAntigens, Differentiation, MyelomonocyticCD68 MoleculeCell LineChromonesFemaleHumansInsulin-Like Growth Factor IInsulin-Like Growth Factor IIMaleMembrane Glycoproteins2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-oneAntibodies, NeutralizingAntigens, CDAntigens, Differentiation, MyelomonocyticCD68 antigen, humanCD68 MoleculeChromonesIGF1 protein, humanIGF2 protein, humanINSR protein, humanInsulin-Like Growth Factor IInsulin-Like Growth Factor IIMembrane GlycoproteinsMorpholinesMRC1 protein, humanMTOR protein, humanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktReceptor, InsulinReceptors, ImmunologicSomatomedinsTOR Serine-Threonine Kinasescancer stemnessIGFM2‑like TAMsPI3K/AKT/mTOR pathwaythyroid cancer

Identifiers

PMID34184083
PMCPMC8258465
OpenAlexW3174977286

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.